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Abstract 
There is growing appreciation that mechanical signals can be as important as chemical and 
electrical signals in biology. To include such signals in a systems biology description for 
understanding pathobiology and developing therapies, quantitative experiments on how 
solution phase and surface chemistry together produce biologically relevant mechanical 
signals are needed. Due to the appearance of drug-resistance hospital “superbugs”, a system 
of large current interest is the destruction of bacteria by antibiotics forming bound drug/target 
complexes which stress the bacterial cell membranes. Here we use nanomechanical 
cantilevers as surface stress sensors together with equilibrium theory to describe 
quantitatively the mechanical response of a surface receptor to different antibiotics in the 
presence of competing ligands in solution. The antibiotics examined are the standard, FDA 
approved drug of last resort, vancomycin, as well as yet-to-be approved oritavancin, which 
shows promise for controlling vancomycin resistant infections. The work reveals variations 
among strong and weak competing ligands, such as proteins in human serum, which 
determine dosages in drug therapies. These findings further enhance our understanding of the 
biophysical mode of action of the antibiotics and will help develop better treatments, 
including choice of drugs as well as dosages, against pathogens.  
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Biochemical systems, such as hormones and transmitters, generate signals in target cells by 
interacting with surface receptors. When an effector molecule and a surface receptor 
combine, a new structural entity is formed1, and the associated stress provides a mechanical 
signal for subsequent biological activity. For example, the antibiotic vancomycin (Van) binds 
to bacterial cell wall precursors to disrupt membrane integrity, effectively stopping the 
bacteria from forming a rigid network of peptides on the cell surface2,3. Competing molecules 
in solution can affect such binding: in antimicrobial therapy, serum proteins are inhibitors 
which reduce the efficacy of drugs4,5 while the competing soluble ligands such as diacetyl 
Lysine-D-Alanine-D-Alanine or diacetyl vancomycin susceptible receptors (Ac-VSR), an 
analogue to the bacterial cell wall peptide precursors6 are thought to enhance the ability of 
drugs to inhibit bacterial cell growth in a clinical setting7.  
 
Serum proteins bind to drugs in blood and in so doing reduce the free concentration of active 
drug and its penetration into cell tissues. Accordingly, a drug that is bound to blood serum is 
no longer available to target the pathogenic organisms and so it is antibacterially inactive. 
Thus, quantifying active free drug concentrations in comparison to the total inhibitory 
concentration administered is important for determining the correct and safe patient dosage. 
Furthermore, understanding the full impact of competitive ligands on the activity of selective 
inhibitors is important for the design of effective drug molecules to control infections as well 
as for determining dose levels. Even so, we are unaware of experiments exploring how 
interactions between competing inhibitory ligands and drug molecules can alter the 
mechanical properties of surface bound receptors to regulate the efficacy of drugs.  
 
Here we describe a new methodology to monitor the interactions of molecules in solution and 
their impact on the surface mechanics of receptors to evaluate drug action in a competitive 
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environment. We formulate a mathematical model to quantify surface stress changes where 
the reactions are occurring in solution and at the surfaces (Fig. 1). As depicted in Figure 1, we 
performed assays without physically separating bound from unbound drugs, which is more 
representative of the physiological environment. We propose the hypothesis that interaction 
between a selective inhibitor and competing ligand in solution affects surface action, which 
controls pharmacological efficacy. We test this hypothesis on two powerful antibiotics; Van 
as a model compound and oritavancin (Ori) as a new drug, respectively. Van has been used 
extensively in tissue engineering and in controlled drug release studies8. It is currently in 
clinical use as one of the last powerful antibiotics against methicillin-resistant Staphylococcus 
aureus (MRSA) as well as Clostridium difficile infections (CDI), and, indeed the recently 
identified multidrug-resistant clones of MRSA9. In contrast, Ori is a semi-synthetic 
lipoglycopeptide in clinical development against serious gram-positive infections caused by 
MRSA10. 
 
Nanomechanical Detection of Ligand-Receptor Interactions 
To measure ligand-receptor interactions necessary to generate changes in surface stress and 
to decouple chemistry from surface mechanics, we selected a cantilever technique. As a 
stress sensor of surface bound receptors, the cantilever technology is unrivalled. All 
conventional tests such as filter binding assays11, equilibrium dialysis12, fluorescence 
polarisation immunoassay (FPIA)13 or surface plasmon resonance (SPR)14 measure optical 
signatures of chemical binding, which do not yield the most important property for 
mechanical signalling, namely surface stress. Cantilevers, with subnanometer sensitivity14-17 
allow direct monitoring and simultaneous quantitation of solution and surface reactions in a 
single step where specificity is achieved by using in-situ referencing15-18. The reactions are 
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quantified by tracking stress changes induced from the ligand-receptor interactions causing 
cantilever bending deflections, measured optically15 or electrically18.  
 
To probe surface stresses due to drug-target interactions, arrays of cantilevers were 
functionalised with surface biomimetic capture molecules, namely vancomycin-susceptible 
receptors (or VSR), analogues to bacterial cell wall precursors that present un-cross-linked 
peptide motifs terminating in the sequence Lysine-D-Alanine-D- Alanine6,19,20. Artefacts that 
produce non-specific signals were overcome by carrying out differential measurements 
where we subtracted reference mercaptoundecyl tri(ethylene glycol) thiol (PEG)-coated 
cantilever bending signals from the VSR signals. The bio-specific binding efficiency was 
further enhanced by the passivation of the "bottom" surface of the cantilevers using PEG-
silane (Supplementary information). 
 
Impact of Weak Competing Ligands on the Efficacy of Drugs 
Serum proteins, a vital component of plasma in the transport of drugs, lipids or steroid 
hormones bind weakly to antibiotics21 and display strong inhibitory effects4,5 and therefore 
serve as a good model for investigating the impact of weak competing ligands. Figure 2 
shows the differential bending signals obtained after injection of blood serum and 
Polysorbate 80 (PS80)22, as well as after injection of 3 μM Van and 0.5 μM Ori. Remarkably, 
antibiotics were detected even in 98% whole blood serum (Fig. 2b and c). The increasing 
noise with serum concentrations observed in our measurements was probably caused by the 
scattering of the laser light by serum proteins. Furthermore, as the serum concentration 
increases, the differential stress signals decrease because of the binding of drug molecules to 
blood serum. The cantilever deflection signal is proportional to the quantity of active free 
drug in the physiological medium, so the bending response is a measure of the effectiveness 
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of dosage and correspondingly, a realistic in-vitro susceptibility test for the drugs. We thus 
can directly quantitate mechanically the effectiveness of dosages without prior amplification 
steps (for example FPIA). For this purpose, our approach unambiguously identifies the 
deflections caused by specific interactions between drugs in blood serum and the surface 
receptors yielding the first experimental evidence that drug-serum complexes only reduce 
surface stress (Fig. 2b-c). 
 
In pharmacology, the potency of drugs is often quoted as IC50, the concentration of antagonist 
that gives rise to 50% inhibition of the activity of a selective inhibitor23. To quantify the IC50 
of drug-serum interactions, a wider range of serum concentrations in the presence of all 
antibiotics were investigated and the results of the equilibrium differential surface stress 
summarised in Figure 2d. Equation (1), whose detailed derivation is given in the 
Supplementary information, was used to calculate IC50 values: 
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where σeq corresponds to equilibrium surface stress, σmin is the constant of proportionality 
which corresponds to the minimum surface stress generated by a selective inhibitor (ligand1) 
in the presence of large excess of the concentration of competitive ligand (ligand2) and σmax 
is the constant of proportionality which corresponds to the maximum surface stress generated 
by ligand1 in the absence of ligand2. The analysis shown in Figure 2d and in Table S1 is the 
outcome of the fit of equation (1) superposed onto measured antibiotic differential stress 
signals revealing IC50 values in whole serum; 700 ± 100 μM for Van and 408 ± 70 μM for 
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Ori. Although Ori’s dose is 6 times lower than Van, a relatively higher concentration of 
serum proteins was required to inhibit its surface stress on the cantilever. 
 
Impact of Strong Competing Ligands on the Efficacy of Drugs 
To further examine the role of competing soluble ligands on the surface functionality of 
drugs, we utilised Ac-VSR because of its strong µM interactions with antibiotics in 
solution6,19,20. Again, the inhibitory effect was quantified by varying the concentrations of the 
soluble ligand while keeping the total antibiotic concentrations [Van] and [Ori] constant at 50 
µM and 0.1 µM respectively. These particular antibiotic concentrations were chosen because: 
i) they give relatively large mechanical bending signals, ii) are found to fall within the linear 
portions of the Langmuir Adsorption Isotherm, and iii) are readily inhibited by adding 
reasonable concentrations of the solubilised ligands. Figure 3 shows the outcome of drug-
target binding interactions in the presence of Ac-VSR. Our measurements reveal that for 500 
µM competing ligand concentration, the interactions of all antibiotics at a surface were ∼ 
40% inhibited despite having intial doses differing by a factor of 500. The equilibrium 
surface stress at each antibiotic concentration was measured on at least 4 arrays, and the 
resulting stress data sets were then modeled by equation (1), yielding IC50 of 110 ± 10 μM for 
Van and 400 ± 70 μM for Ori respectively. The enhanced IC50 values observed in the 
presence of analogous competing ligand to the surface receptor is not surprising given that in 
a whole bacteria assay, a large amount of inhibitory ligand24 is required to induce complete 
loss of activity (Supplementary Table S2).  
 
Figure 4 shows that for lower antibiotic concentrations (100 pM – 0.1 µM), particularly of 
oritavancin, 50 – 60 min was required to reach thermodynamic pseudo-equilibrium. In 
contrast, for higher antibiotic concentrations (0.5 µM – 10 µM), equilibrium was reached in 
9 
 
 
just under 3 minutes. Our experiments show that cantilever detection sensitivity is governed 
to a large extent by the degree of the affinity/avidity of the receptor-ligand interactions. For 
example, for the antibiotic drug vancomycin, which binds predominantly as a monomer, the 
minimum cantilever-detectable drug concentration is 10 nM15. This is 30 times more 
sensitive than established approaches such as the commercially available SPR method, for 
which the detection of 300 nM vancomycin has been reported (Table 1). To demonstrate the 
ultimate sensitivity and to provide the evidence for our hypothesis that affinity/avidity 
determines detection sensitivity, we measured the binding of oritavancin, a novel antibiotic, 
against the same surface capture receptor as vancomycin. The data reveal a detection 
sensitivity of 100 pM antibiotic concentration in buffer (Fig. 4), which is two orders of 
magnitude lower than for vancomycin15. 
 
Figure 5a & b show the equilibrium differential bending signals obtained from blood serum 
concentration fixed at 98% after injection of different concentrations of antibiotics. The 
minimal response of in-situ reference PEG cantilevers, which is anti-adsorbative, even for 
very high antibiotic concentrations provides strong evidence of surface specific binding to 
VSR. Moreover, to compare the variations in the magnitude of surface stress signals within 
each antibiotic and from across antibiotics (Fig. 2-5), we plotted cantilever bending deflection 
signals over the same time scales of 40 mins. 
 
Modelling the System of Antibiotic, Solvent and Surface Activity  
To quantify the correlation between solution matrix and surface mechanics (Supplementary 
information), we began by considering model (I) shown in Figure 1a where the stress induced 
in surface bound receptors in the presence of ligand1 scales as a function of ligand 
concentration. The changes in surface mechanics are monitored by the expression:  
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         (2) 
where σ1 corresponds to surface stress, n is the stoichiometric coefficient of the reactions 
without a competing soluble ligand and K1 is the surface thermodynamic equilibrium 
dissociation constant. It is raised to the power n to ensure that K1 maintains the dimension of 
concentration as n varies. Setting n = 1 yields the Langmuir isotherm where the reactions 
occur independently, while n > 1 corresponds to positive co-operative interactions and n < 1 
is a measure of negative co-operativity. While equation (2) yields the key parameters K1 and 
σmax, responsible for quantifying surface binding interactions and the mechanical properties, 
it cannot quantify free ligand concentrations in solution, essential for biological activity. Thus 
we devised a second model (II), illustrated in Figure 1b, where we consider the simultaneous 
interactions, whose strength is given by K3 , between surface bound receptors and multiplexed 
soluble ligands. Again, the changes in surface mechanics induced by the reactions with 
competing ligand2 in solution and at the surface targets are quantified by the expression, (see 
Supplementary information) where the solution phase stoichiometric coefficient m =1, the 
system volume is infinite, and [ligand2] >>[ligand1]: 
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where σ2 corresponds to surface stress in the presence of competing ligands and K3 is the 
solution thermodynamic equilibrium dissociation constant. Eq. (3), which reduces to Eq. (1) 
if the concentration of [ligand1] is fixed and n = 1, offers a particular understanding of 
ligand-receptor interactions and may help to design better assays to detect activation or 
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inhibition of complex signal transduction pathways in response to selective inhibitors or 
treatments. The difference between models (I) and (II) is that in the latter case we account for 
the concentration of free drug molecules in a physiological medium which governs their 
activity via competitive serum. Accordingly, we modeled our stress data using equation (3) as 
a description of ligand-receptor interactions to quantify simultaneous surface and solution 
reactions. The resulting analysis allows us to evaluate the impact of serum binding on the 
concentration of active free drugs (Fig. 5c & d). The parameters σmax, m, K1 and K3,  which 
characterise the surface mechanics and solution matrix are coupled in a statistical sense. 
Therefore, to determine K3, we first carried out a nonlinear least-square best fit of equation 
(3) to the antibiotic stress data from phosphate buffer, i.e. in the absence of serum proteins. 
This was achieved by setting [ligand2] = 0. The maximum surface stress signals, σmax 
generated by Van and Ori were found to be 27 ± 3 mN/m and 36.8 ± 3.8 mN/m respectively. 
The K1 in phosphate buffer was calculated as 0.5 ± 0.2 µM for Van and 0.04 ± 0.1 µM for Ori 
while the stoichiometric coefficients values were n = 1 for Van and n = 1.2 ± 0.2 for Ori 
respectively. These binding constants from the cantilever measurements are in good 
agreement with other sensor methods, for example SPR (Table 1).  
 
Inspection of the denominator of Eq. (3) shows that the effect of serum on the nano-
mechanics of surface drug-target interactions is entirely via the term (K1/K3)[serum]; in this 
case ligand2 = serum. We therefore repeated the process of least-square best fits of Eq. (3) to 
the antibiotic stress data in the presence of serum proteins, where the parameters σmax, n, and 
K1 were fixed to their respective values in phosphate buffer while the serum concentration 
was fixed at ∼98%. The K3 for Van binding to serum proteins in solution was found to be 500 
± 90 µM, 2000 times weaker than for Ori where K3 is 30 ± 6 µM. Supplementary Table S1 
shows a summary of K3 for solution phase interactions via equations (1) and (4) in different 
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media and makes comparison with direct mechanical quantitation, where the K3 values 
observed in whole serum, within experimental error are in good agreement, validating 
equation (3). The fact that σmax and stoichiometric coefficients are the same in buffer and 
serum makes it unlikely that serum-drug complexes bind surface bacterial cell wall targets. 
Supplementary Table S2 shows a summary of K1 for surface interactions in different media 
and makes comparison with reported Minimum Inhibition Concentration (MIC) values from 
whole bacterial assays28, where the MICs’ observed in whole serum are in good agreement 
with the K1’s from cantilever measurements.  
 
The chemical equilibrium equations for the model of Fig. 1b can also be solved analytically 
(Supplementary information) to yield an expression for the fraction fb of drugs bound to 
serum proteins: 
 
        (4) 
Using Eq. (4), our results for K3 together with [Van] = 3μM, [Ori] = 0.5 μM and [serum] = 
98% result in ~54% bound for Van and ~95% bound for Ori. This is in agreement with 
previous work where the proportion of Van-serum complex in the literature averages 55% in 
humans, although a wide range (10 to 80% bound) has been reported21 while the effective 
amount of Ori bound to serum proteins varies between 50 and 95%29. Equilibrium dialysis 
and related techniques have been the methods of choice to study blood-serum interactions but 
are subject to errors30, limiting their accuracy at clinically relevant antibiotic doses which 
stand at (3-27 µM)31. In contrast, the mechanical quantitation of efficacious drug 
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concentration in blood serum is not limited by such errors and by using the low end of 
therapeutic antibiotic doses of 3 µM Van and 0.5 µM Ori, within the clinically relevant 
therapeutic window (3-27 µM)31 as administered in hospitals, we find that the active free 
drug concentrations are ~1.4 µM Van and ~0.1 µM Ori. The reported MICs in whole serum 
for Van is ~0.7 µM and for Ori, it is ~1 µM for most staphylococci28, and the agreement with 
our cantilever-based measurements (Supplementary Table S2) demonstrates convincingly 
that surface mechanics is strongly linked to the efficacy of drugs. 
 
Novel Interactions of Bound Complexes in Solvents with Surface Receptors  
For serum in solution, the agreement of cantilever data over the full range of antibiotic and 
serum concentrations with Eq. (3) indicates the validity of the model in Fig. 1b with the rate 
constants K2 and K4 neglected. We show now that when we replace serum proteins with small 
peptides, this simplification matches the actions of vancomycin but not for oritavancin. Here 
we take advantage of the fact that direct comparison of equations (1) and (3) for m = 1 yields 
the conventional Cheng-Prusoff equation23: 
 
        (5) 
If K3 and IC50 are known, equation (5) can be used to characterise the surface binding affinity 
of selective inhibitors in a competitive environment. Accordingly, we estimated the K1 values 
for drug binding to surface receptors in the presence of analogues Ac-VSR using K3 for Van 
∼1 μM6 and ∼ 3.8 μM20 for Ori; our estimate of K1 for Van is ∼0.46 ± 0.02 μM and ∼ (9.6 
±2.4) x 10-4 μM for Ori. The K1 for Van is indistinguishable from that measured by varying 
[Van] in phosphate buffer while for Ori it is a remarkable 50 times smaller than in phosphate 
buffer, yielding the lowest known dissociation constant for a receptor-drug binding 
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interaction involving a small drug molecule. To test the accuracy of these values, we 
substituted Eq. (4) into Eq. (1) where the K1 was fixed to its respective value in phosphate 
buffer to calculate the expected nano-mechanical stress. The results are plotted as dashed 
lines in Figure 3c & d for comparison to the solid lines where Eq. (1) with K1 was allowed to 
vary. The comparison validates the conclusion that there is nothing unusual about 
vancomycin, where the solid and dashed lines are negligibly different, while roughly an order 
of magnitude leftward shift for oritavancin confirms the widely differing K1’s obtained 
indirectly from Eq. (5) and directly from varying [Ori] in phosphate buffer in the absence of 
competing Ac-VSR ligands. The implication is that for oritavancin and Ac-VSR in solution, 
the pathways labeled by K2 and K4 in Fig 1b cannot be neglected, meaning that in the 
presence of these ligands, the complexes bound in solution can also bind to membrane 
surface targets and therefore induce stress.  
 
Conclusions 
Our comprehensive experimental study at clinically relevant antibiotic drug doses (3-27 
µM)31 of the transduction between chemical and mechanical signals has uncovered the role of 
strong and weak competing ligands in the functionality of drugs and shows quantitatively 
how surface binding affinity is correlated with competing solution phase processes32,33. It 
represents to our knowledge the first use of nanomechanics for solving a practical 
pharmacological problem, namely that of comparing a novel drug such as oritavancin, with 
an older drug, vancomycin, threatened by evolving antimicrobial resistance. Beyond 
providing surface binding constants, our in-vitro competitive inhibition assays provide 
guidance and understanding as to the therapeutic doses needed in whole blood. More 
generally, we have shown that by combining classical chemical equilibrium theory with 
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nanomechanical measurements, we can produce a compact quantitative description of a basic 
biological system involving mechanical events and multiple chemical pathways. 
 
The experiments demonstrate that distinct changes of surface mechanics are drug-specific 
and that the solvent matrix plays a fundamental role in modulating the surface mechanics via 
straightforward inhibition due to competitive binding. It is clear that direct mechanical 
quantitation of the effectiveness of dosages using equation (3) without prior amplification 
steps will lead to progress in pharmacology and new insights into optimal clinical regimes, 
such as combination therapies. The experiments provide a blueprint for further studies to 
determine the role of chemistry and mechanics in membrane-bound receptors and proteins, 
which in turn will lead to the design of both better drugs as well as diagnostic platforms 
based on surface sensing layers. Perhaps the most obvious diagnostic application is to 
measure the active free drug availability in blood for a particular medical target and thereby 
determine appropriate doses tailored for individualised patients. With suitably engineered 
surface probes such as miniaturised cantilever arrays in a flow-through geometry, the 
diagnostic device would be paired with customised drug delivery for anaesthesia, anti-cancer, 
anti-HIV and antibacterial therapies. 
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Additional Information 
Supplementary information accompanies this paper at 
www.nature.com/naturenanotechnology Reprints and permission information is available 
online at http://npg.nature.com/reprints and permissions/. Correspondence and requests for 
materials should be addressed to JWN and RAM.  
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METHODS 
Specificity of drug-target interactions. A strategy of passivation of the ‘bottom’ side and in-
line referencing against a control cantilever was adopted to ensure measurements of drug-
target interactions resulted in specific signals only. 
 
Experimental errors. The surface stress data error bars in each set of measurements were 
determined as the standard deviation of the surface stress data fitted measurements from four 
separate cantilever chips. 
 
Role of competing soluble ligands. The exact relationship between surface action and the 
size/nature of the competing ligands was tested by using serum proteins (67 kDa) and 
diacetyl Lysine-D-Alanine-D-Alanine (Ac-VSR) (0.37 kDa) analogues to bacterial cell wall 
precursors (Bact. Analog). Comparison between Figs. 3 and 5 show quite similar stress 
responses for the large and small molecule in solution and the same basic equations (1) and 
(3) apply to all data. While our measurements demonstrate that the strength of surface drug-
receptor binding interactions is not affected by the presence of serum proteins, the drug-
diacetyl Lysine-D-Alanine-D-Alanine complexes (or drug-Ac-VSR) in solution phase was 
observed to interact with the surface bound receptors to induce the stress, driving the 
enhanced efficacy of surface binding affinity for antibiotics (Fig. 1b). Thus, our results show 
that in contrast to large-sized competing serum proteins, the pathways labeled by K2 and K4 in 
Fig 1b for small drug molecules in the presence of small sized strong competing ligands 
cannot be neglected. In summary, (i) the drug molecules which are not significantly affected 
by the competing ligands in solution may bind to the surface targets without reducing their 
surface binding affinities, (ii) a bound drug-target complex in solution may increase the 
polarisation of a dimer binding pocket and in turn promote surface dimerisation, greatly 
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enhancing the binding strength to the surface receptors, and (iii) in the case of weak 
competing ligands, the binding of a drug molecule to a ligand in solution may block the 
access of surface active binding sites. We demonstrated these principles by evaluating the 
modes of action of the clinically important glycopeptide group of antibiotics to reveal how 
they are affected by the solution matrix. We show that Ori/Ori, Ori/serum, Van/Van and 
Van/serum solution matrices under physiological conditions yield nanomechanical stress 
assays which are in good agreement with the drugs’ efficacy. 
 
To demonstrate that the model as shown in (ii) can be used to enhance the surface binding 
interactions and to control the functionality of drug molecules, we implemented this model 
according to the complex interactions derived from the combinations of Ori/diacetyl Lysine-
D-Alanine-D-Alanine and Van/diacetyl Lysine-D-Alanine-D-Alanine (Supplementary Table 
S2). We find that in contrast to drug/serum complex, the drug/diacetyl Lysine-D-Alanine-D-
Alanine complexes of Ori over Van improves surface binding activity 500-fold. Such 
mechanism is particularly important for drug molecules, where the increased surface binding 
activity, can lead to increased surface stress to alter the mechanics of bound surface receptors, 
boosting the efficiency of drugs for killing pathogens. This is a major advance because it 
means that the efficiency of drugs may be enhanced by administering a combinational 
therapy of drug/small sized strong competing ligands. Future work will investigate the extent 
of solution matrices of Ori/Van/serum, Ori/Van/serum/diacetyl Lysine-D-Alanine-D-Alanine, 
Van/serum/diacetyl Lysine-D-Alanine-D-AlanineandOri/serum/diacetyl Lysine-D-Alanine-
D-Alanine on cantilevers to test if these combinations can improve the efficacy over 
Van/serum and Ori/serum complexes applicable to the present day clinical practice. 
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A Table and Figure captions 
 
Description  Receptor Detection 
sensitivity  
SPR 
(nM) 
K1  
SPR  
(µM) 
Detection 
sensitivity 
cantilever 
 (nM) 
 
K1 Cantilever 
(µM) 
Van  VSR 310 
(ref. 25) 
300 
(ref. 26) 
1.1 
(ref. 26) 
10 
(ref. 15) 
0.5 ± 0.2 
      
Ori  VSR n/a 0.07 
(ref. 27) 
0.1 0.04 ± 0.01 
n/a SPR value not available 
 
Table 1 The detection sensitivity of drug-target interactions on cantilever arrays compared 
with the SPR measurements.  
 
Figure 1: Exploiting the nanomechanics of drug-target interactions to investigate the impact 
of dosing and competing ligands on the functionality of drug molecules; (a) Schematic 
representation of solution and surface interactions, where molecules can bind to the surface 
tethered receptors to form a bound complex. The efficacy is measured for a model bacteria 
cell wall analogue tethered to one side of a cantilever surface. (b) Schematic representation of 
the overall concept for therapeutic efficacy, where molecules can bind to the surface bound 
receptors to form a complex or interact with a competing ligand in three dimensional (3D) 
solution to form drug-target complex while blocking the selective inhibitors from binding to 
the surface bound receptors. (c) Schematic representation of an array of eight rectangular 
silicon cantilevers, each measuring 500 μm long, 100 μm wide and 1μm thick. The bending 
of all cantilevers is monitored in parallel using time-multiplexed optical beam detection on a 
single photodetector. The red beam is the laser which is focused at the free end of each 
cantilever sensor to monitor the cantilever bending deflections. The surface bound receptors 
are represented by vertical sticks, while the antibiotic drug molecules are shown as blue 
chemical structural cartoons and the serum protein molecules are represented by the red 
symbols (circle). (d) Schematic representation of complex blood environment from blood 
vessel to demonstrate the challenge of real time nanomechanical detection of active free 
drugs in bloodstream and to investigate the impact of the nature of solvent matrix on the 
bioactivity of drugs. 
 
Figure 2: The nanomechanics of drug-target interactions in weak competing ligand at 
clinically relevant concentrations; (a) The differential surfaces stress for Van binding from 
600 μM (4g/dL) of pure model human serum albumin (HSA) to test the specificity and 
sensitivity of nanomechanics of drug-target interactions in a complex liquid media such as 
blood serum. The differential PEG reference signal is shown in black. The cantilevers 
generally bend downwards due to steric and electrostatic repulsive interactions between 
surface bound drug-target complexes. A negative signal corresponds to a compressive surface 
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stress and the downward bending of the cantilever. The greyed-out area represents the 
injection of serum without the drug for control measurements lasting for 5 mins to establish a 
baseline. (b) The differential bending signal of 3 μM Van in 0% (green), 50% (blue) and 
98% (red) blood serum. The corresponding differential PEG reference signals for all three 
serum concentrations are shown in green, blue and red. The greyed-out area represents the 
injection of serum without the drug for control measurements lasting for 5 mins to establish a 
baseline. (c) The corresponding differential bending signals of 0.5 μM Ori in 0% (green), 
50% (blue) and 98% (red) blood serum.The greyed-out area represents the injection of serum 
without the drug for control measurements lasting for 5 mins to establish a baseline. (d) The 
differential surface stress for 3 μM Van monitored as a function of model pure human serum 
albumin (orange) and pooled normal whole human blood serum (NHS) (blue) concentrations 
diluted in phosphate buffer with PS80 described by the Eq. (1) (solid lines) to calculate IC50. 
The corresponding differential surface stress for 0.5 μM Ori monitored as a function of 
model pure human serum albumin (light blue) and pooled normal whole human serum (NHS) 
(red) concentrations diluted in phosphate buffer with PS80 described by the Eq. (1) (solid 
lines) to calculate IC50. The surface stress data error bars were determined as the standard 
deviation of the surface stress data fitted measurements from four separate cantilever chips. 
 
Figure 3: The nanomechanics of drug-target interactions in the presence of strong competing 
ligand at clinically relevant concentrations; (a) The differential bending signal of 50 μM Van 
in 0 μM (green), 50 μM (blue) and 500 μM (red) (Bact. Analog or Ac-VSR). The differential 
PEG reference signal is shown in black. The greyed-out area represents the injection of 
diacetyl Lysine-D-Alanine-D-Alanine (Ac-VSR) analogues to bacterial cell wall precursors 
(Bact. Analog) without the drug for control measurements lasting for 10 mins to establish a 
baseline. (b) The corresponding differential bending signals of 0.1 μM Ori in 0 μM (green), 
30 μM (light blue) and 500 μM (red) (Bact. Analog or Ac-VSR). The greyed-out area 
represents the injection of diacetyl Lysine-D-Alanine-D-Alanine (Ac-VSR) analogues to 
bacterial cell wall precursors (Bact. Analog) without the drug for control measurements 
lasting for 10 mins to establish a baseline. (c) A semi-log plot showing the measured 
differential stress response for surface bound receptors as a function of diacetyl Lysine-D-
Alanine-D-Alanine (Bact. Analog or Ac-VSR) concentrations in solution, superimposed on 
the results of the fit according to Eq. (1) for Van shown by solid diamond symbols in blue. 
The data are described by Eq. (1) for K1 = 0.5 ± 0.2 µM (solid lines, black) and for K1 = 0.46 
± 0.02 µM (dotted lines, orange). The surface stress data error bars were determined as the 
standard deviation of the surface stress data fitted measurements from four separate cantilever 
chips. (d) A semi-log plot showing the measured differential stress response for surface 
bound receptors as a function of diacetyl Lysine-D-Alanine-D-Alanine concentrations in 
solution, superimposed on the results of the fit according to Eq. (1) for Ori shown by solid 
circle symbols in red. The data are described by Eq. (1) for K1= 0.04 ± 0.1 µM (solid lines, 
black) and for K1 = (9.6 ± 2.4) x 10-4 µM (dotted lines, orange). The surface stress data error 
bars were determined as the standard deviation of the surface stress data fitted measurements 
from four separate cantilever chips. 
 
Figure 4: Investigating the mechanics of drug-target interactions using cantilever sensor 
arrays. The differential bending signals in buffer for VSR signals of 0.1, 10, 50, 100 and 500 
nM Ori respectively. The differential PEG reference signal is shown (PEG2 – PEG1 black). 
The downward bending signal corresponds to a compressive (repulsive) surface stress and the 
minimum detectable drug concentration is 100 pM, showing that the cantilever differential 
bending signal scales with the drug load. The greyed-out area represents the injection of 
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phosphate buffer solution without the drug for control measurement lasting for 10 mins to 
establish a baseline. 
 
Figure 5: The nanomechanical quantitation of drug-target interactions in whole blood serum 
at clinically relevant concentrations; (a) The differential bending signal at 98% whole blood 
serum for 1 μM Van (orange), 5 μM Van (green) and 50 μM Van (light blue). The 
differential PEG reference signal is shown in black. The greyed-out area represents the 
injection of serum without drug for control measurement lasting for 5 mins to establish a 
baseline. (b) The corresponding differential bending signals at 98% whole blood serum for 
1.5 μM Ori (red), 3 μM Ori (blue) and 5 μM Ori (green). The differential PEG reference 
signal is shown in black. The greyed-out area represents the injection of serum without the 
drug for control measurement lasting for 5 mins to establish a baseline.(c) A semi-log plot 
showing the measured differential surface stress response for surface bound receptors as a 
function of drug concentrations in solution, superimposed on the results of the fit according 
to Model (II) Eq. (3) for Van in buffer (open symbols in blue) where [ligand2] = 0 and in 
whole blood serum (solid symbols in blue) where the parameters σmax, m, and K1 were fixed 
to their respective values in phosphate buffer while the serum concentration was fixed at 
∼98% to calculate K3. The surface stress data error bars were determined as the standard 
deviation of the surface stress data fitted measurements from four separate cantilever chips. 
(d) A semi-log plot showing the measured differential surface stress response for surface 
bound receptors as a function of drug concentrations in solution, superimposed on the results 
of the fit according to Model (II) Eq. (3) for Ori in buffer (open symbols in wine) where 
[ligand2] = 0 and in whole blood serum (solid symbols in red) where the parameters σmax, m, 
and K1 were fixed to their respective values in phosphate buffer while the serum 
concentration was fixed at ∼98% to calculate K3.The surface stress data error bars were 
determined as the standard deviation of the surface stress data fitted measurements from four 
separate cantilever chips. 
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